drugset / Trial / NCT00669071

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

NCT00669071

Phase 4 Terminated 56 enrolled Galderma R&D
RandomizedSingle-groupSingle-blindTreatment

Summary

This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects diagnosed with moderate to severe melasma during a 10 week treatment period.

Timeline

Start
2008-01
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroquinone Small molecule 4 % Topical
Comparator Tretinoin Small molecule 0.05 % Topical
Comparator fluocinolone acetonide Small molecule 0.01 % Topical